Recommandations françaises du comité de cancérologie de l’AFU pour le cancer de la prostate : cancer de prostate métastatique hormono-sensible–actualisation 2020-Reference-Cited by-同舟云学术

Recommandations françaises du comité de cancérologie de l’AFU pour le cancer de la prostate : cancer de prostate métastatique hormono-sensible–actualisation 2020

Published:2020-06 Issue:8-9 Volume:30 Page:430-438
ISSN:1166-7087
Container-title:Progrès en Urologie
language:fr
Short-container-title:Progrès en Urologie

Author:

Rozet F.,Hennequin C.,Beuzeboc P.,Mathieu R.,Mongiat-Artus P.,Beauval J.-B.,Cormier L.,Fromont-Hankard G.,Ploussard G.,Renard-Penna R.,Brureau L.,Méjean A.

Publisher

Elsevier BV

Subject

Urology

Reference34 articles.

1. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial;Fizazi;Lancet Oncol,2019

2. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015

3. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial;Buelens;Urol Oncol,2018

4. Oligometastatic prostate cancer: reality or figment of imagination?;Foster;Cancer,2019

5. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation;Guckenberger;Lancet Oncol,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signatures moléculaires dans les cancers de la prostate résistants à la castration : état des lieux;Bulletin du Cancer;2022-09